Incannex Healthcare Limited (NASDAQ: IXHL) (ASX:IHL), announced the filing of a provisional patent application directed to the use of IHL-42X for the treatment of obstructive sleep apnea (‘OSA’).
Syros Pharmaceuticals (NASDAQ:SYRS) reported quarterly losses of $(0.41) per share which beat the analyst consensus estimate of $(0.44) by 6.82 percent. This is a 4.65 percent increase over losses of $(0.43) per share